Imugene Limited (ASX: IMU) has announced a positive final complete survival data from its Phase 2 study of HER-Vaxx in Her-2/Neu overexpressing advanced/metastatic gastric/GEJ cancer subsequent analysis of safety and efficacy data.
The final analysis in the randomized Phase 2 trial exhibited statistically important overall survival Hazard Ratio of 0.585 (80% 2-sided CI: 0.368, 0.930). Further, HER-Vaxx presented a reduced risk of death of 41.5% in the HER-Vaxx plus chemotherapy group compared to chemotherapy alone.
The median overall survival for patients getting HER-Vaxx along with chemotherapy was 13.9 months, which was 8.3 months in patients treated with chemotherapy alone.
The Phase 2 trial confirms a favourable survival result with no additional toxicity for HER-Vaxx together with standard-of-care chemotherapy over chemotherapy alone.
HERIZON-extension Cohort Review Committee confirmed a dose of HER-Vaxx 100µg for future studies will begin soon.
At AEST 11:15 AM, IMU shares are trading at $0.205, up 24.242% from the previous close.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
